Approval · Notice of Compliance 16532 · 2015
HYTRIN: Notice of Compliance 16532
Issued January 15, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16532
- Date
- January 15, 2015
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification numbers
- Therapeutic class
- Antihypertensiv agent, symptomatic treatment of benign prsotatic hyperplasia (bph)
Products in this notice
Medicinal ingredients
- TERAZOSIN HCL 1 MG per TAB
- TERAZOSIN HCL 2 MG per TAB
- TERAZOSIN HCL 5 MG per TAB
- TERAZOSIN HCL 10 MG per TAB